A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Hereditary Transthyretin-mediated (ATTRv) AmyloidosisPolyneuropathy
Interventions
DRUG

Patisiran

Patisiran-lipid complex injection, for intravenous use

Trial Locations (27)

15212

Clinical Trial Site, Pittsburgh

15232

Clinical Trial Site, Pittsburgh

17602

Clinical Trial Site, Lancaster

18015

Clinical Trial Site, Bethlehem

18103

Clinical Trial Site, Allentown

27599

Clinical Trial Site, Chapel Hill

28207

Clinical Trial Site, Charlotte

30517

Clinical Trial Site, Braselton

31201

Clinical Trial Site, Macon

32224

Clinical Trial Site, Jacksonville

33609

Clinical Trial Site, Tampa

38138

Clinical Trial Site, Germantown

39216

Clinical Trial Site, Jackson

43210

Clinical Trial Site, Columbus

48202

Clinical Trial Site, Detroit

53226

Clinical Trial Site, Milwaukee

60611

Clinical Trial Site, Chicago

60612

Clinical Trial Site, Chicago

64111

Clinical Trial Site, Kansas City

68198

Clinical Trial Site, Omaha

78229

Clinical Trial Site, San Antonio

78756

Clinical Trial Site, Austin

80045

Clinical Trial Site, Aurora

90095

Clinical Trial Site, Los Angeles

92103

Clinical Trial Site, San Diego

06030

Clinical Trial Site, Farmington

02111

Clinical Trial Site, Boston

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY